AmpliPhis novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S.

AmpliPhi’s novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S viagradanmark.eu viagradanmark.eu . Aureus lung disease model Results presented at the Joint Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and An infection 2015 conference AmpliPhi Biosciences Corporation , a worldwide leader in the advancement of bacteriophage-based antibacterial therapies to take care of drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung disease model.